Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2024 Nov;22(9):582-592.
doi: 10.6004/jnccn.2024.0057.

NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024

John A Thompson  1 , Bryan J Schneider  2 , Julie Brahmer  3 , Mohammad Abu Zaid  4 , Amaka Achufusi  5 , Philippe Armand  6 , Meghan K Berkenstock  3 , Bonnie Bermas  7 , Tawnie Braaten  8 , Lihua E Budde  9 , Saurin Chokshi  10 , Zachary D Crees  11 , Marianne Davies  12 , Changchun Deng  13 , Yaron Gesthalter  14 , Michael Jain  15 , Prantesh Jain  16 , Andrew Jallouk  17 , Benjamin H Kaffenberger  18 , Maya Khalil  19 , Melissa G Lechner  20 , Tianhong Li  21 , Alissa Marr  22 , Suzanne McGettigan  23 , Jordan McPherson  8 , Theresa Medina  24 , Nisha A Mohindra  25 , Anthony J Olszanski  26 , Olalekan Oluwole  17 , Sandip P Patel  27 , Jason Prosek  18 , Sunil Reddy  28 , Pankti Reid  29 , John Ryan  30 , Mabel Ryder  31 , Huda Salman  4 , Bianca Santomasso  32 , Scott Shofer  33 , Jeffrey A Sosman  17 , Yinghong Wang  34 , Vlad G Zaha  7 , Stephen Zucker  35 , Megan Lyons  36 , Ajibola Awotiwon  36 , Lisa Hang  36
Affiliations
Practice Guideline

NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024

John A Thompson et al. J Natl Compr Canc Netw. 2024 Nov.

Abstract

The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell-engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources